Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2016

Rose April A N, Annis Matthew G, Frederick Dennie T, Biondini Marco, Dong Zhifeng, Kwong Lawrence, Chin Lynda, Keler Tibor, Hawthorne Thomas, Watson Ian R, Flaherty Keith T, Siegel Peter M

Abstract excerpt

PURPOSE: To determine if BRAF and/or MEK inhibitor-induced GPNMB expression renders melanomas sensitive to CDX-011, an antibody-drug conjugate targeting GPNMB. EXPERIMENTAL DESIGN: The Cancer Genome Atlas melanoma dataset was interrogated for a panel of MITF-regulated melanosomal differentiation antigens, including GPNMB. BRAF-mutant melanoma cell lines treated with BRAF or MEK inhibitors were assessed for GPNMB...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Immunoconjugates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Melanoma, Cutaneous Malignant

Share to Membrane Glycoproteins

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 27515299
DOI: 10.1158/1078-0432.CCR-16-1192
PMCID: PMC6168941

Genes

GPNMB
BRAF
MITF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.PMID 27515299Read ↗

Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma.Semantic proximity Read ↗

Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell linesSemantic proximity Read ↗

Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patientsSemantic proximity Read ↗

Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanomaSemantic proximity Read ↗

G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in MelanomaSemantic proximity Read ↗

Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma.Semantic proximity Read ↗

Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma.Semantic proximity Read ↗

The MNK1/2-eIF4E axis drives melanoma plasticity, progression, and resistance to immunotherapySemantic proximity Read ↗

Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK ResistanceSemantic proximity Read ↗

Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapySemantic proximity Read ↗

Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.Semantic proximity Read ↗

Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.